Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-022 with reference trastuzumab

Autor: Sergey M. Alexeev, Andrey V. Khorinko, Guzel Z. Mukhametshina, Konstantin G. Shelepen, Olga N. Burdaeva, Sergey A. Kulik, Chiradoni Thugappa Satheesh, Kirti Srivastava, Mummaneni Vikranth, Fedor Kryukov, Anastasia N. Paltusova, Mariya S. Shustova, Roman A. Ivanov

Publikováno v: BMC Cancer, Vol 20, Iss 1, Pp 1-10 (2020)

Abstract Background BCD-022 is a trastuzumab biosimilar which was shown to be equivalent to reference trastuzumab in a wide panel of physicochemical studies as well as preclinical studies in vitro and in vivo. International multicenter phase III clin

Externí odkaz: https://doaj.org/article/91e85db418314c6180848ec4b818e417

Mutation landscape of multiple myeloma measurable residual disease: identification of targets for precision medicine

Autor: Lucie Broskevicova, Kateřina Growková, Jana Filipova, Jiří Minařík, Roman Hájek, Ludek Pour, Giovanni Stracquadanio, Lucie Rihova, Fedor Kryukov, Juli R. Bagó, Lubica Harvanova, Zuzana Chyra, Lucie Cerna, Michal Simicek, Vladimir Maisnar, Martina Zatopkova, Renata Bezdekova, Matous Hrdinka, David Žihala, Alexandra Jungova, Viola Fanfani, Tereza Sevcikova, Jana Smejkalová, Tereza Popkova, Anjana Anilkumar Sithara, Tomas Jelinek

Publikováno v: Zátopková, M, Ševčíková, T, Fanfani, V, Chyra, Z, Rihova, L, Bezdekova, R, Žihala, D, Growková, K, Filipova, J, Černá, L, Broskevičová, L, Kryukov, F, Minařík, J, Smejkalová, J, Maisnar, V, Harvanová, L, Pour, L, Jungova, A, Popková, T, Bago, J R, Anilkumar Sithara, A, Hrdinka, M, Jelinek, T, Šimíček, M, Stracquadanio, G & Hajek, R 2021, ' Mutation landscape of multiple myeloma measurable residual disease : identification of targets for precision medicine ', Blood Advances . https://doi.org/10.1182/bloodadvances.2020003876
Blood Advances

Multiple myeloma (MM) measurable residual disease (MRD) persisting after treatment is an adverse prognostic factor for progression free survival (PFS) and overall survival.1Genomic mutations occurred in the remaining clonal aberrant plasma cells (A-P

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::416410420e5d98efe4fb72c3bcc142a6
https://doi.org/10.1182/bloodadvances.2020003876

Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma.

Autor: Lenka Besse, Lenka Sedlarikova, Fedor Kryukov, Jana Nekvindova, Lenka Radova, Ondrej Slaby, Petr Kuglik, Martina Almasi, Miroslav Penka, Marta Krejci, Zdenek Adam, Ludek Pour, Sabina Sevcikova, Roman Hajek

Publikováno v: PLoS ONE, Vol 10, Iss 9, p e0137294 (2015)

Poor outcome of extramedullary disease in multiple myeloma patients and lack of outcome predictors prompt continued search for new markers of the disease. In this report, we show circulating microRNA distinguishing multiple myeloma patients with extr

Externí odkaz: https://doaj.org/article/1c18f8435a574f45a2322070f78e88ad

Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance

Autor: Lenka Kubiczkova, Fedor Kryukov, Ondrej Slaby, Elena Dementyeva, Jiri Jarkovsky, Jana Nekvindova, Lenka Radova, Henrieta Greslikova, Petr Kuglik, Eva Vetesnikova, Ludek Pour, Zdenek Adam, Sabina Sevcikova, Roman Hajek

Publikováno v: Haematologica, Vol 99, Iss 3 (2014)

Multiple myeloma still remains incurable in the majority of cases prompting a further search for new and better prognostic markers. Emerging evidence has suggested that circulating microRNAs can serve as minimally invasive biomarkers for multiple mye

Externí odkaz: https://doaj.org/article/8f3f68e7ced84c7bb0ffbab5100aec83

Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-022 with reference trastuzumab

Autor: Konstantin G. Shelepen, Anastasia N. Paltusova, Fedor Kryukov, Sergey M. Alexeev, Mariya S. Shustova, Sergey A. Kulik, Kirti Srivastava, Chiradoni Thugappa Satheesh, Olga Burdaeva, Guzel Z. Mukhametshina, Andrey V. Khorinko, Roman Ivanov, Mummaneni Vikranth

Publikováno v: BMC Cancer, Vol 20, Iss 1, Pp 1-10 (2020)
BMC Cancer

Background BCD-022 is a trastuzumab biosimilar which was shown to be equivalent to reference trastuzumab in a wide panel of physicochemical studies as well as preclinical studies in vitro and in vivo. International multicenter phase III clinical tria

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e583dc70946efde96993e08fa512bc31
https://doi.org/10.1186/s12885-020-07247-9